Adalimumab Biosimilars: Are They as Effective as the Original?
"A deep dive into the production and characterization of Adalimumab biosimilars, exploring their potential as cost-effective alternatives in autoimmune disease treatment."
Recombinant antibodies have revolutionized the treatment of autoimmune diseases, offering targeted therapies that can significantly improve patients' lives. These antibodies, produced in living cells, are complex proteins, and their effectiveness hinges on their precise structure and function. Post-translational modifications (PTMs), which occur after the protein is synthesized, play a crucial role in determining these characteristics.
Adalimumab, a well-known anti-TNF-α antibody, is a prime example of such a therapeutic. It works by neutralizing TNF-α, a key inflammatory molecule involved in autoimmune disorders like rheumatoid arthritis and Crohn's disease. While Adalimumab has proven highly effective, its high cost has limited accessibility for many patients. This is where biosimilars come into play.
Biosimilars are essentially 'copycat' versions of original biologic drugs like Adalimumab. While not identical, they are designed to be highly similar in terms of safety and efficacy, offering a more affordable alternative. This article delves into the production and characterization of an Adalimumab biosimilar, comparing it to the original drug, Cinorra, to assess its potential as a cost-effective treatment option.
Adalimumab Biosimilar Uptake and Product Variation
An observational study published in 2025 monitored the effectiveness and possible adverse effects of switching from originator adalimumab to Hyrimoz in clinical practice. Biosimilar demand grew rapidly from March to April 2024 after Caremark formulary changes, with Hyrimoz moving ahead in adalimumab patient use. Uptake had previously been described as slower than that of many other biologic and specialty loss-of-exclusivity events, likely because of brand contracting practices and large PBM payer controls. A global review identified 29 adalimumab products, with notable variation in device and formulation features among the 14 analyzed in depth.
The Totality of Evidence
Biosimilar development relies on comparative structural, physicochemical, functional, and clinical assessments. Together, these analyses form a totality-of-evidence approach intended to demonstrate that there are no clinically meaningful differences from the reference product. Reviews of preclinical methods emphasize that each method has distinct strengths and limitations, so multiple approaches contribute different information to the assessment. Human-factors research has also compared the injection success rate of the adalimumab-fkjp Hulio autoinjector with the Humira autoinjector.
A Developing Treatment Landscape
The history of adalimumab biosimilars reflects the broader development of biologic medicines and their follow-on products. As these products became available, evaluation increasingly focused on demonstrating similarity rather than reproducing every aspect of the originator's development program. The field remains dynamic, and the timing and significance of milestones may differ across diseases, regions, and regulatory systems.
HEK-293T Cells: A Promising Platform for Adalimumab Production
Traditionally, Adalimumab and its biosimilars are produced using Chinese Hamster Ovary (CHO) cells. However, human cell lines like HEK-293T offer a compelling alternative. These cells are capable of producing proteins with human-like PTMs, potentially leading to better efficacy and reduced immunogenicity.
- Structural Similarity: Circular dichroism spectroscopy confirmed a strong structural similarity between the Adalimumab biosimilar produced in HEK-293T cells and Cinorra.
- Binding Affinity: The biosimilar's ability to bind to and neutralize TNF-α was comparable to that of Cinorra, indicating similar efficacy in targeting the inflammatory molecule.
- Biological Activity: The biosimilar effectively neutralized TNF-α-mediated cellular cytotoxicity, further demonstrating its functional similarity to Cinorra.
Evidence From Switching Studies
Recent research has examined both single and repeated switching between originator adalimumab and biosimilars. A 2025 study evaluated ADA-AACF, also called MSB11022, in rheumatoid arthritis patients transitioning from the reference product, with disease activity and drug survival assessed over 12 months. Another report described a phase 3, open-label, randomized, parallel-group study of multiple switching between PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis. A retrospective chart review also explored multi-switch safety and efficacy in inflammatory bowel disease patients receiving adalimumab-adaz or adalimumab-atto, while a 2026 report noted that real-world evidence after biosimilar initiation remains limited.
Switching Is Not Uniformly Successful
A systematic review reported that switching between reference adalimumab and biosimilar adalimumab had no impact on efficacy, safety, or immunogenicity in patients with rheumatoid arthritis, psoriasis, and inflammatory bowel disease. However, a psoriasis report described switches from Humira to Imraldi that were not all successful, with some patients requiring a switchback to the originator or another biosimilar. A retrospective real-world study in hidradenitis suppurativa also concluded that switching between adalimumab products was associated with a greater likelihood of loss of effectiveness. These findings indicate that the overall evidence is favorable but does not rule out unsuccessful switches in particular settings.
Beyond Clinical Similarity
By March 2025, 10 adalimumab biosimilars had been approved and marketed, and all shared the indications of the reference product. They nevertheless differed in factors such as product design and other features relevant to use. A Navitus study examined real-world clinical outcomes from a structured program that transitioned patients from Humira to FDA-approved biosimilar alternatives. Comparisons therefore involve not only the reference product and biosimilar designation, but also the practical characteristics of individual products and transition programs.
The Future of Adalimumab Biosimilars
The successful production and characterization of an Adalimumab biosimilar in HEK-293T cells holds significant implications for the future of autoimmune disease treatment. The potential for cost-effective production, coupled with the advantages of human-like PTMs, makes this platform a promising avenue for developing more accessible and potentially more effective therapies.
A Balanced Interpretation
The available evidence supports a generally favorable view of adalimumab biosimilar similarity, particularly when structural, functional, clinical, and real-world findings are considered together. At the same time, individual switching experiences may vary, and unsuccessful transitions have been reported in some patient groups. Conclusions should therefore distinguish population-level evidence from the needs and outcomes of individual patients.
Expanding Real-World Evidence
Future work will likely place greater emphasis on longer-term outcomes after switching, repeated-switch experience, and the practical use of different devices and formulations. Continued study may help clarify which patient or treatment factors are associated with successful continuation or a need to change therapy. Evidence from routine clinical practice will remain important as biosimilar use expands.
Access Depends on More Than Approval
The broader impact of adalimumab biosimilars depends not only on regulatory approval and clinical similarity, but also on formulary decisions, payer controls, contracting practices, and product availability. These systems can slow or accelerate uptake independently of the underlying evidence. Differences in devices and formulations may also affect how patients and clinicians experience the transition.
Patient Experience After Switching
Real-world studies have examined biosimilar use among patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis, as well as treatment-naive patients with hidradenitis suppurativa. One multicenter study compared patients remaining on originator adalimumab with those switched to a biosimilar after 16 weeks. Another study surveyed continuation of adalimumab biosimilars after mandated switching at a single academic medical center. These reports highlight that continuation, effectiveness, and the experience of changing products are important outcomes alongside formal clinical efficacy.
Further research is needed to fully explore the long-term effects and immunogenicity of Adalimumab biosimilars produced in HEK-293T cells. Clinical trials comparing these biosimilars to the original drug and other biosimilars will be crucial in establishing their safety and efficacy in real-world settings.
As healthcare systems worldwide grapple with rising drug costs, the development of affordable biosimilars like Adalimumab is paramount. Continued innovation in production platforms and rigorous characterization studies will pave the way for a future where effective autoimmune disease treatments are accessible to all who need them.